Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Munich - Delayed Quote EUR

Daiichi Sankyo Co Ltd (D4S.MU)

Compare
21.80
-0.13
(-0.59%)
At close: February 21 at 8:05:24 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for D4S.MU

Recent News: D4S.MU

View More
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
Pharmaceutical Technology 6 days ago
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?
Zacks 6 days ago
IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says

IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says
Reuters 16 days ago
Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail

Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail
Business Wire 19 days ago
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Business Wire 23 days ago
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Pharmaceutical Technology 23 days ago
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
Business Wire 23 days ago
TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse

TROPION-Lung12 Phase 3 Trial Initiated Evaluating DATROWAY® as Part of Adjuvant Regimen for Patients with Early-Stage Non-Small Cell Lung Cancer at High Risk of Relapse
Business Wire 23 days ago
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients

FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
Pharmaceutical Technology 25 days ago
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
Zacks 26 days ago
ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies

ENHERTU® Approved in the U.S. as First HER2 Directed Therapy for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following Disease Progression After One or More Endocrine Therapies
Business Wire 27 days ago
View More

Related Tickers

AMG.HA Amgen Inc
286.85
+1.34%
 
BRM.MU Bristol-Myers Squibb Co
52.86
+0.69%
 
ABBV34.SA AbbVie Inc.
72.27
+1.22%
 
ORNAV.HE Orion Oyj
51.80
0.00%
 
LLY0.DU Eli Lilly and Co
20.80
+1.96%
 
NOVNEE.SW Novartis AG
98.04
+1.42%
 
COPNz.XC
 
0O59.IL Sanofi
104.04
+0.64%
 
SNW.F Sanofi
103.16
+0.19%
 
NOTA.F Novartis AG
100.00
-0.50%